A University of Bradford‑supported biotech start‑up has been named among the top 17 companies nationally to be selected for a flagship Innovate UK‑funded programme.
Hado Therapeutics, supported by the University of Bradford’s Enterprise Fellowship Programme, has secured a place on the LYVA Labs Future Medicines Accelerator, part of the Innovate UK Biomedical Catalyst Accelerator programme.
The programme is designed to fast‑track the UK’s most promising biotech ventures and support the future of medicines.
Dr Harsha Kantamneni, CEO and co-founder of Hado Therapeutics and a lecturer at the University of Bradford, said: “To be shortlisted for the Innovate UK Biomedical Catalyst Accelerator – Future Medicines programme is prestigious.
“Drug development is a long journey.
“Embedding Hado through the University’s Enterprise Fellowship Programme and its Institute of Cancer Therapeutics has been transformative.”
Hado Therapeutics is developing novel dual‑targeting molecules designed to act across more than one disease pathway.
Its current pipeline includes programmes targeting Parkinson’s disease and glioblastoma, an aggressive form of brain cancer.
Sonya Bachra Byrne, Enterprise Development Manager, added: “Our focus is on helping innovators turn strong ideas into real-world impact.
“The Enterprise Fellowship Programme gives academics and researchers the time, structure and support to build commercially credible ventures, while strengthening their entrepreneurial skills along the way.”
Leave a comment